Search results
Results from the WOW.Com Content Network
Side effects from intra-articular administration can include joint pain, swelling, lameness, and, rarely, infection of the joint. Intramuscular injection can cause dose-dependent inflammation and bleeding, since PSGAG is an analogue of the anticoagulant heparin. [4] In dogs, this may manifest as bleeding from the nose or as bloody stools. [7]
Half the dogs received bedinvetmab and half the dogs received a sterile saline injection every 28 days for a total of three doses. [5] Before treatment and on various days throughout the study, owners used the Canine Brief Pain Inventory (CBPI) assessment tool to measure the severity of the dog's pain and the degree to which the pain interfered ...
Polystyrene sulfonates are a group of medications used to treat high blood potassium. [1] Effects generally take hours to days. [1] They are also used to remove potassium, calcium, and sodium from solutions in technical applications. Common side effects include loss of appetite, gastrointestinal upset, constipation, and low blood calcium. [1]
Potassium binders are medications that bind potassium ions in the gastrointestinal tract, thereby preventing its intestinal absorption. This category formerly consisted solely of polystyrene sulfonate, a polyanionic resin attached to a cation, administered either orally or by retention enema to patients who are at risk of developing hyperkalaemia (abnormal high serum potassium levels).
Block copolymers can be made this way. RDRP allows for control of molecular weight and dispersity. However, this is very difficult to achieve and instead a pseudo-living polymerization occurs with only partial control of molecular weight and dispersity. [15] ATRP and RAFT are the main types of complete radical polymerization.
Polystyrene integrated solid foams are not commonly used in biomedical applications but have shown promise as a new drug delivery vehicle. The manipulation of the porous foam networks is a fundamental component in solid foam dosing – affecting variables such as dissolution, adsorption, and drug diffusion. [4]
Pimobendan is indicated for the management of the signs of mild, moderate, or severe congestive heart failure in dogs due to clinical myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM); [1] [7] and for use with concurrent therapy for congestive heart failure (e.g.,furosemide, etc.) as appropriate on a case-by-case basis. [1]
These adverse effects can be reduced by using lower concentrations of the polymer, so that it gets naturally released throughout the body. Something else to consider regarding PLGA biocompatibility is the location at which the polymer is implanted or placed in the body.